ATR AptarGroup
- 153.190
- +0.910+0.60%
- 153.190
- 0.0000.00%
AptarGroup News
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $170
AptarGroup's Strong Market Position and Growth Potential Affirm Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $168
Bank of America Securities Sticks to Their Buy Rating for AptarGroup (ATR)
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR) and Aura Biosciences Inc (AURA)
AptarGroup Analyst Ratings
BofA Securities Adjusts Price Target on AptarGroup to $163 From $160
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
AptarGroup Analyst Ratings
Analysts Conflicted on These Healthcare Names: AptarGroup (ATR) and Community Health (CYH)
AptarGroup's Strong Q1 Performance and Robust Pharmaceutical Growth Justify Buy Rating
AptarGroup Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Sarepta Therapeutics (SRPT) and AptarGroup (ATR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (ATR), Halozyme (HALO) and Bausch Health Companies (BHC)
AptarGroup's Strong Performance and Growth Prospects Merit a Buy Rating
Baird Upgrades AptarGroup to Outperform, Raises Price Target to $150
AptarGroup Analyst Ratings
Hold Rating on AptarGroup Amid Modest Q3 Profits and Uncertain Q4 Outlook
Positive Financial Outlook Spurs 'Buy' Rating for AptarGroup: A Detailed Analysis of 3Q Performance and 4Q Projections
Analysis
Price Target
No Data
